methyl 1-acetylindoline-5-acetate | 81709-42-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: methyl 1-acetylindoline-5-acetate
• 英文别名: 1-acetyl-2,3-dihydro-1H-indole-5-acetic acid, methyl ester；methyl 2-(1-acetyl-2,3-dihydroindol-5-yl)acetate
• CAS: 81709-42-4
• 化学式: C₁₃H₁₅NO₃
• 分子量: 233.267
• InChiKey: VOVZZPQHNBDAHG-UHFFFAOYSA-N

物化性质

• 沸点：
  438.8±40.0 °C(Predicted)
• 密度：
  1.204±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 1-acetylindoline-5-acetate 在 盐酸 、 硼烷 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 methyl 1-(5-hydroxypentanoyl)indoline-5-acetate
  参考文献：
  名称：

  Photorelease of Carboxylic Acids from 1-Acyl-7-nitroindolines in Aqueous Solution:  Rapid and Efficient Photorelease of l-Glutamate¹

  摘要：

  DOI：

  10.1021/ja990931e
• 作为产物：
  描述：

  1,5-二乙酰基二氢吲哚 以 氯仿 为溶剂， 生成 methyl 1-acetylindoline-5-acetate
  参考文献：
  名称：

  Indole-5-acetamides for treatment of migraine

  摘要：

  本发明涉及一般式(I)的化合物：其中R.sub.1、R.sub.3、R.sub.4、R.sub.6和R.sub.7，可以相同也可以不同，分别代表氢原子或烷基基团；R.sub.2代表氢原子或烷基、芳基、芳基烷基、环烷基或烯基基团；或者R.sub.1和R.sub.2与它们连接的氮原子一起形成一个饱和的单环5到7成员环，该环可能还含有另外的杂原子功能基团；R.sub.5代表氢原子或烷基或烯基基团；或者R.sub.4和R.sub.5一起形成芳基烷基亚甲基基团；Alk代表一个含有两个或三个碳原子的烷基链，该链可以未被取代或被不超过两个C.sub.1-3烷基基团取代；X代表氧原子或硫原子；以及其生理上可接受的盐、溶剂化合物和生物前体。所述化合物被描述为治疗偏头痛的潜在有用化合物，并且可以以传统方式制备为含有一种或多种医药上可接受的载体或赋形剂的药物组合物。公开了制备这些化合物的各种方法，例如，涉及将具有适当的5-位置上的腈基团的吲哚与适当的含氧或硫化合物反应以在吲哚核上引入所需的酰胺或硫酰胺基团的过程。

  公开号：

  US04650810A1

文献信息

• 1-Acyl-7-nitroindoline derivatives, their preparation and their use as photocleavable precursors
  申请人：Medical Research Council

  公开号：US06765014B1

  公开（公告）日：2004-07-20

  Photoreleasable compounds comprising a caging moiety linked to an effector moiety represented by structural formula (I) wherein R1 is hydrogen; C1-10 alkyl or substituted alkyl; O(CH2)n—Y; N(COZ)(CH2)mY; or N[(CH2)mY′[(CH2)NY]; R2 and R3 are independently selected from: hydrogen; C1-10 alkyl or substituted alkyl; or R2 and R3 together are cycloalkyl; R4 is hydrogen; C1-10 alkyl or substituted alkyl; phenyl or substituted phenyl; (CH2)nY; or (CH2)mO(CH2)nY; wherein m and n are independently between 1 and 10; Y and Y′ are independently selected from hydrogen, CO2H or salts thereof or OPO32−, Z is hydrogen or C1-10 alkyl or substituted alkyl; and, X is an effector moiety or a group capable of being coupled or converted to an effector moiety, which are capable of releasing the effector moiety on irradiation, typically by flash irradiation with UV light. The photoreleasable compounds can therefor be used to deliver biologically active effector moieties such as neuroactive amino acids or metal chelators to sites where their activity is required.

  含有一个与结构式（I）所代表的效应子结构式相连的光释放化合物，其中R1为氢；C1-10烷基或取代烷基；O(CH2)n—Y；N(COZ)(CH2)mY；或N[(CH2)mY′[(CH2)NY]; R2和R3分别选择自：氢；C1-10烷基或取代烷基；或R2和R3一起为环烷基；R4为氢；C1-10烷基或取代烷基；苯基或取代苯基；(CH2)nY；或(CH2)mO(CH2)nY；其中m和n分别在1和10之间；Y和Y′分别选择自氢、CO2H或其盐或OPO32−，Z为氢或C1-10烷基或取代烷基；X为效应子或能够与效应子偶联或转化的基团，能够在照射下释放效应子，通常通过紫外光的闪烁照射。因此，这些光释放化合物可用于将生物活性效应子，如神经活性氨基酸或金属螯合剂，输送到需要其活性的部位。
• [EN] 7-NITROINDOLINE DERIVATIVES AND THEIR USES<br/>[FR] DERIVES DE 7-NITROINDOLINE ET LEURS UTILISATIONS
  申请人：MEDICAL RES COUNCIL

  公开号：WO2004085394A1

  公开（公告）日：2004-10-07

  7-nitroindoline compounds are disclosed that comprise a triplet sensitising group such as substituted or unsubstituted benzophenone group and can be used to cage effector species. In particular, the inclusion of a triplet sensitising group linked to the 4 or 5 position of a 7-nitroindoline derivative provides compounds which can be photolysed to release the effector species with unexpectedly enhanced photolysis efficiency. The triplet sensitising group may be linked directly to the 7-nitroindoline or via a spacer group. In some examples, the triplet sensitising group and/or the spacer group can be selected to enhance other properties of the caged compound such as its solubility, spectroscopic properties or stability (e.g. stability of the linkage between the nitroindoline moiety and the triplet sensitiser). This can help to improve the performance of the caged compound, especially in aqueous environments containing dissolved oxygen.

  本文介绍了一种包含三重敏化基团的7-硝基吲哚化合物，例如取代或未取代的苯基酮基团，并可用于封闭效应物种。特别是，将三重敏化基团连接到7-硝基吲哚衍生物的4或5位上，可提供可光解化合物，其光解效率意外增强，从而释放效应物种。三重敏化基团可以直接连接到7-硝基吲哚或通过间隔基团连接。在某些示例中，可以选择三重敏化基团和/或间隔基团以增强封闭化合物的其他性质，例如其溶解性，光谱性质或稳定性（例如硝基吲哚基团和三重敏化剂之间的连接的稳定性）。这有助于提高封闭化合物的性能，特别是在含有溶解氧的水环境中。
• Arylethanolamine derivatives and their use as agonists of atypical
  申请人：Glaxo Wellcome Inc.

  公开号：US06048872A1

  公开（公告）日：2000-04-11

  The present invention relates to phenethanolamine derivatives of formula (I) wherein R.sup.1 represents an aryl group optionally substituted by one or more substituents selected from halogen, hydroxy, C.sub.1-6 -alkoxy, C.sub.1-6 -alkyl, nitro, cyano, hydroxymethyl and trifluoromethyl; R.sup.2 represents hydrogen or C.sub.1-6 -alkyl; R.sup.3 represents a group (A) where the ring is substituted by one to four further substituents selected from C.sub.1-6 -alkyl, halogen, trifluoromethyl, and C.sub.1-6 -alkoxy; or R.sup.3 represents a group (B) where the aromatic ring is optionally substituted by up to three further substituents selected from C.sub.1-6 -alkyl, halogen, trifluoromethyl, and C.sub.1-6 -alkoxy; R.sup.4 represents hydrogen, or C.sub.1-6 -alkyl; R.sup.5 represents ZCH.sub.2 CO.sub.2 H wherein Z represents a bond, or O; Y represents (CH.sub.2).sub.n where n is 1-3; and physiologically acceptable derivatives thereof; to process for their preparation; and their use in the treatment of conditions susceptible of amelioration by an atypical beta-adrenoceptor agonist.

  本发明涉及公式（I）的苯乙醇胺衍生物，其中R.sup.1代表芳基基团，该基团可以选择地被卤素、羟基、C.sub.1-6-烷氧基、C.sub.1-6-烷基、硝基、氰基、羟甲基和三氟甲基中的一个或多个取代基取代; R.sup.2代表氢或C.sub.1-6-烷基; R.sup.3代表一个(A)基团，其中环被选择自C.sub.1-6-烷基、卤素、三氟甲基和C.sub.1-6-烷氧基的一个到四个进一步取代基取代; 或R.sup.3代表一个(B)基团，其中芳香环可以选择地被最多三个进一步的C.sub.1-6-烷基、卤素、三氟甲基和C.sub.1-6-烷氧基取代; R.sup.4代表氢或C.sub.1-6-烷基; R.sup.5代表ZCH.sub.2CO.sub.2H，其中Z代表键或O; Y代表(CH.sub.2).sub.n，其中n为1-3; 以及其生理上可接受的衍生物的制备方法; 以及它们在通过非典型β-肾上腺素受体激动剂改善的情况的治疗中的用途。
• ARYLETHANOLAMINE DERIVATIVES AND THEIR USE AS AGONISTS OF ATYPICAL BETA-ADRENOCEPTORS
  申请人：GLAXO GROUP LIMITED

  公开号：EP0865421A1

  公开（公告）日：1998-09-23
• 1-ACYL-7-NITROINDOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PHOTOCLEAVABLE PRECURSORS
  申请人：MEDICAL RESEARCH COUNCIL

  公开号：EP1161418A1

  公开（公告）日：2001-12-12